EU, in 2024 exported medicines and pharmaceutical merchandise for 313.4 billion euros | EUROtoday

Imports

Germany (23 billion euros), Belgium (21 billion euros), the Netherlands (15 billion euros) and Italy (14 billion euros) have been the foremost importers of medicinal and pharmaceutical merchandise from international locations exterior the EU, in 2024. In the identical interval Slovenia (17%), Belgium (12%) and Malta (11%) recorded the very best quotas of medicinal merchandise and prescribed drugs of their whole extra-EU imports. Ireland (49 billion euros) and Germany (45 billion euros) had the foremost non-EU business surpluses for medicinal and pharmaceutical merchandise in 2024. Only Romania, Slovakia, Malta, Estonia and the Czech Republic had business deficits.

The Italian image

As for Italy, the finals 2024, as they level out by Farmindustria, “confirm the great contribution to growth”.

Specifically, Italy recorded an export for 53.8 billion euros “equal to over 90% of the production, estimated at 56.1 billion euros”. Italy comment the representatives of Farmindustria, it’s thought-about European hub for manufacturing “among the main countries in terms of pharmaceutical production and 7th world pharmaceutical market”. In 2024 there have been 71 thousand workers with a development of 1.5%, primarily concentrated within the capabilities of R&D and manufacturing (+3%). The different information communicate of “+21.2 billion € of foreign balance of drugs and vaccines, the first sector for surplus”. “Drugs and vaccines – argue from Farmindustria – represent 18% of the overall foreign balance of the manufacturing industry in Italy”. That’s not all. Other information embody +11.2 billion euros of optimistic international stability of the entire of the sector. “The pharmaceutical percentage on the total of manufacturing export went from 3.5% in 2004 to 9.1% in 2024 – they still argue -. Over the past 5 years, pharmaceutical exports have grown by 65% ​​compared to 26% of the other sectors and has basically determined 100% of the growth of pharmaceutical production “. In addition, “in the last 5 years Italy export has grown more than that in other European countries ( +65% compared to +57%)”.

Lithuania: the delicate stability between import and manufacturing of medication

According to the newest official information of the Lithuanian medicinal management service (SMCA), over 90% of the medicines distributed on the nationwide market is imported. Only a marginal share – lower than 10% – is produced regionally, primarily by corporations equivalent to Valentis and Aconitum, lively within the manufacturing of dietary supplements and generic medicine. The predominant companion international locations for import are Germany, Poland, Latvia and, an increasing number of typically, India, the place bodily manufacturing takes place, whereas registration and serialization are managed by EU holders, together with Lithuanian operators. This hybrid system makes it troublesome to obviously classify the origin of many medicines.

The import decisions should not centralized by the State however depend upon the homeowners of the AIC (authorization to make in the marketplace), which resolve on the premise of financial and structural parameters: market worth, inhabitants dimension, reimbursement system, logistical prices and availability of therapeutic options. This method, if on the one hand it ensures flexibility, nevertheless exposes the market to dangers linked to interruptions within the provide chain.